Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSMOS: Simeprevir + Sofosbuvir in Chronic HCV
NCT01466790Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2012
- Primary completion
- Nov 2013
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of simeprevir and sofosbuvir in hepatitis C (HCV) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Sustained Virologic Response 12 Weeks After End of Treatment. Started Jan 2012; status: completed.
02
Drugs
simeprevirsofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01466790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01466790.